AngioDynamics has demonstrated notable revenue growth driven mainly by its Med Tech segment, including platforms like Auryon and NanoKnife, with annual sales nearly quadrupling since FY2019. Despite top-line expansion, the company continues to face operating losses, although trends indicate a narrowing deficit compared to previous years. Macroeconomic pressures such as inflation, tariffs, and labor shortages have constrained gross margins and exacerbated operational costs. Capital allocation remains conservative with limited buybacks and negative free cash flow, reflecting ongoing challenges in achieving profitability. Future growth depends on clinical adoption of innovative products and expanding international market presence, particularly in Europe for NanoKnife.